Adam J. Lamble

1.7k total citations
54 papers, 548 citations indexed

About

Adam J. Lamble is a scholar working on Oncology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Adam J. Lamble has authored 54 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 23 papers in Hematology and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Adam J. Lamble's work include CAR-T cell therapy research (34 papers), Acute Myeloid Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (15 papers). Adam J. Lamble is often cited by papers focused on CAR-T cell therapy research (34 papers), Acute Myeloid Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (15 papers). Adam J. Lamble collaborates with scholars based in United States, United Kingdom and Germany. Adam J. Lamble's co-authors include Evan Lind, Sarah K. Tasian, Rebecca Gardner, Colleen Annesley, Ted Laderas, Shannon K. McWeeney, Todd M. Cooper, Jeffrey Tyner, E. Anders Kolb and Todd A. Alonzo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Immunology.

In The Last Decade

Adam J. Lamble

45 papers receiving 544 citations

Peers

Adam J. Lamble
William B. Donnellan United States
Shilpa Alekar United States
Mayumi Sugita United States
Xinjie Xu United States
Matthew T. Witkowski United States
Frauke M. Schnorfeil Germany
Tara Gregory United States
Montserrat Torrebadell Spain
Hendrik Wessels Germany
Rawan Faramand United States
William B. Donnellan United States
Adam J. Lamble
Citations per year, relative to Adam J. Lamble Adam J. Lamble (= 1×) peers William B. Donnellan

Countries citing papers authored by Adam J. Lamble

Since Specialization
Citations

This map shows the geographic impact of Adam J. Lamble's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam J. Lamble with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam J. Lamble more than expected).

Fields of papers citing papers by Adam J. Lamble

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam J. Lamble. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam J. Lamble. The network helps show where Adam J. Lamble may publish in the future.

Co-authorship network of co-authors of Adam J. Lamble

This figure shows the co-authorship network connecting the top 25 collaborators of Adam J. Lamble. A scholar is included among the top collaborators of Adam J. Lamble based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam J. Lamble. Adam J. Lamble is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lamble, Adam J., Sandra D. Bohling, Kara L. Davis, et al.. (2025). Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement. HemaSphere. 9(11). e70247–e70247.
2.
Lin, Aifen, Adam J. Lamble, Rhonda E. Ries, et al.. (2025). TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia. Blood. 146(Supplement 1). 3470–3470.
3.
Valtis, Yannis K., Surabhi B Vora, Joseph M. Rocco, et al.. (2025). Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL. Journal for ImmunoTherapy of Cancer. 13(9). e012436–e012436.
4.
Huang, Benjamin J., Lauren K. Meyer, Todd A. Alonzo, et al.. (2025). Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 43(17). 1961–1971.
5.
Myers, Regina M., Yimei Li, Adam J. Lamble, et al.. (2025). Clinical Factors Associated with Prolonged Cytopenias in Children and Young Adults Treated with CD19-Directed CAR T Cells (CAR19) for Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 31(2). S96–S96.
6.
Annesley, Colleen, Adam J. Lamble, Corinne Summers, et al.. (2024). Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Advances. 9(9). 2068–2078. 2 indexed citations
7.
8.
Kovach, Alexandra E., Sara Silbert, Annie Luong, et al.. (2024). Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch. Blood. 144(Supplement 1). 2799–2799.
9.
10.
Silbert, Sara, Kai Rejeski, Keith Wilson, et al.. (2024). Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 145(11). 1136–1148. 5 indexed citations
11.
Summers, Corinne, Karen M. Chisholm, Sandra D. Bohling, et al.. (2023). Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy. Blood Advances. 7(12). 2825–2830. 4 indexed citations
12.
Schultz, Liora M., Elad Jacoby, Adam J. Lamble, et al.. (2023). Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium. Transplantation and Cellular Therapy. 29(10). 592–593. 2 indexed citations
13.
Duenas, Devan M., Jenna Voutsinas, Vicky Wu, et al.. (2023). Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.. Journal of Clinical Oncology. 41(16_suppl). 10026–10026. 1 indexed citations
14.
Winestone, Lena E., Erin Sullivan, Qian Wu, et al.. (2023). Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients. Transplantation and Cellular Therapy. 29(6). 356.e1–356.e7. 16 indexed citations
15.
Huang, Benjamin J., Lauren K. Meyer, Adam J. Lamble, et al.. (2023). Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 142(Supplement 1). 655–655. 1 indexed citations
16.
17.
Lamble, Adam J., Lisa Eidenschink Brodersen, Todd A. Alonzo, et al.. (2021). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 40(3). 252–261. 26 indexed citations
18.
Leonard, Jessica, Yoko Kosaka, Dorian LaTocha, et al.. (2020). Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 137(7). 939–944. 17 indexed citations
19.
Leonard, Jessica, Yoko Kosaka, Adam J. Lamble, et al.. (2018). Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 1547–1547.
20.
Lamble, Adam J., Yoko Kosaka, Pierrette Lo, et al.. (2015). Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia. Blood. 126(23). 1374–1374. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William B. Donnellan Breakdown of academic impact, for papers by Shilpa Alekar Breakdown of academic impact, for papers by Mayumi Sugita Breakdown of academic impact, for papers by Xinjie Xu Breakdown of academic impact, for papers by Matthew T. Witkowski Breakdown of academic impact, for papers by Frauke M. Schnorfeil Breakdown of academic impact, for papers by Tara Gregory Breakdown of academic impact, for papers by Montserrat Torrebadell Breakdown of academic impact, for papers by Hendrik Wessels Breakdown of academic impact, for papers by Rawan Faramand
Rankless by CCL
2026